Development of antitumor biguanides targeting energy metabolism and stress responses in the tumor microenvironment.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
01 03 2021
01 03 2021
Historique:
received:
20
12
2020
accepted:
05
02
2021
entrez:
2
3
2021
pubmed:
3
3
2021
medline:
15
12
2021
Statut:
epublish
Résumé
To develop antitumor drugs capable of targeting energy metabolism in the tumor microenvironment, we produced a series of potent new biguanide derivatives via structural modification of the arylbiguanide scaffold. We then conducted biological screening using hypoxia inducible factor (HIF)-1- and unfolded protein response (UPR)-dependent reporter assays and selective cytotoxicity assay under low glucose conditions. Homologation studies of aryl-(CH
Identifiants
pubmed: 33649449
doi: 10.1038/s41598-021-83708-w
pii: 10.1038/s41598-021-83708-w
pmc: PMC7921556
doi:
Substances chimiques
Antineoplastic Agents
0
Biguanides
0
Neoplasm Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4852Références
Biochem Soc Trans. 2016 Oct 15;44(5):1499-1505
pubmed: 27911732
Cell Biol Toxicol. 2018 Aug;34(4):279-290
pubmed: 28871429
Bioorg Med Chem Lett. 2002 Mar 25;12(6):951-4
pubmed: 11959001
Biopharm Drug Dispos. 2009 Nov;30(8):476-84
pubmed: 19768675
J Natl Cancer Inst. 2004 Sep 1;96(17):1300-10
pubmed: 15339968
Oxid Med Cell Longev. 2017;2017:7038603
pubmed: 28874953
J Biol Chem. 1996 Dec 20;271(51):32529-37
pubmed: 8955077
PLoS One. 2012;7(9):e45845
pubmed: 23029271
Int J Cancer. 2015 Mar 15;136(6):E534-44
pubmed: 25196138
BMC Biol. 2016 Aug 09;14:65
pubmed: 27506389
Int J Mol Sci. 2019 Feb 11;20(3):
pubmed: 30754624
Biol Chem. 2018 Mar 28;399(4):321-335
pubmed: 29272251
Cancer Manag Res. 2019 Apr 17;11:3295-3313
pubmed: 31114366
Reprod Toxicol. 2017 Jun;70:97-101
pubmed: 27832950
Trends Mol Med. 2020 Jan;26(1):119-134
pubmed: 31327706
Cell. 2008 Sep 5;134(5):703-7
pubmed: 18775299
J Med Chem. 2020 Dec 10;63(23):14276-14307
pubmed: 33103432
Cell Metab. 2020 Sep 1;32(3):341-352
pubmed: 32668195
PLoS One. 2017 Feb 8;12(2):e0170975
pubmed: 28178278
Mol Cell Biochem. 2016 Aug;419(1-2):29-40
pubmed: 27392906
Nature. 2014 Apr 3;508(7494):108-12
pubmed: 24670634
Clin Cancer Res. 2018 Jun 1;24(11):2482-2490
pubmed: 29420223
PLoS One. 2014 Jan 08;9(1):e85436
pubmed: 24416410
Adv Drug Deliv Rev. 2009 Nov 30;61(14):1250-75
pubmed: 19716393
Oncotarget. 2016 Jun 28;7(26):40621-40629
pubmed: 27259254
Clin Cancer Res. 2017 Sep 15;23(18):5639-5647
pubmed: 28611197
Nat Chem Biol. 2015 Jan;11(1):9-15
pubmed: 25517383
Cancer Commun (Lond). 2019 Oct 25;39(1):63
pubmed: 31653274
Cell Chem Biol. 2017 Sep 21;24(9):1161-1180
pubmed: 28938091
Cancer Res. 2009 May 15;69(10):4225-34
pubmed: 19435925
Pharmacol Res. 2016 Sep;111:237-246
pubmed: 27317943
Int J Mol Sci. 2019 Jul 05;20(13):
pubmed: 31284513
Acta Pharm. 2018 Dec 1;68(4):517-524
pubmed: 31259708
J Comb Chem. 2004 Sep-Oct;6(5):776-82
pubmed: 15360213
Antioxid Redox Signal. 2020 Feb 10;32(5):285-308
pubmed: 31841375
Cell Res. 2018 Mar;28(3):265-280
pubmed: 29219147
Appl Biochem Biotechnol. 2019 Aug;188(4):1009-1021
pubmed: 30783947
Melanoma Res. 2020 Feb;30(1):1-13
pubmed: 31116160
Cancers (Basel). 2018 Sep 18;10(9):
pubmed: 30231564
Bioorg Med Chem. 2011 Sep 15;19(18):5392-401
pubmed: 21865046
Drug Des Devel Ther. 2014 Jun 06;8:701-17
pubmed: 24944508
J Med Chem. 1975 Sep;18(9):873-83
pubmed: 1159709
Proc Natl Acad Sci U S A. 2015 Sep 15;112(37):11642-7
pubmed: 26324945
J Clin Invest. 2013 Sep;123(9):3693-700
pubmed: 23999444
Nat Med. 2018 Jul;24(7):1036-1046
pubmed: 29892070
Front Cell Dev Biol. 2017 Apr 26;5:43
pubmed: 28491867
Cancer Res. 2010 Mar 15;70(6):2465-75
pubmed: 20215500
Cell Rep. 2019 Dec 3;29(10):3009-3018.e4
pubmed: 31801069